Last10K.com

Proqr Therapeutics N.V. (PRQR) SEC Filing 6-K Foreign Issuer Report for the period ending Tuesday, April 20, 2021

Proqr Therapeutics N.V.

HISTORY TOOLS
CIK: 1612940 Ticker: PRQR

View differences made from one to another to evaluate Proqr Therapeutics N.V.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Proqr Therapeutics N.V..

Continue

Assess how Proqr Therapeutics N.V.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Proqr Therapeutics N.V.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Proqr Therapeutics N.V. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Exhibit 99.2: Additional Exhibits
Exhibit 99.3: Additional Exhibits
Exhibit 99.4: Additional Exhibits
Ticker: PRQR
CIK: 1612940
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001104659-21-052208
Submitted to the SEC: Tue Apr 20 2021 7:47:44 AM EST
Accepted by the SEC: Tue Apr 20 2021
Period: Tuesday, April 20, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/prqr/0001104659-21-052208.htm